The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties.
about
Metorphamide: isolation, structure, and biologic activity of an amidated opioid octapeptide from bovine brainDifferential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonistsNovel developments with selective, non-peptidic kappa-opioid receptor agonistsPsychotomimesis mediated by kappa opiate receptorsRole of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized ratsThe inhibitory effects of alpha(2)-adrenoceptor agonists on gastrointestinal transit during croton oil-induced intestinal inflammationRole of central and peripheral opiate receptors in the effects of fentanyl on analgesia, ventilation and arterial blood-gas chemistry in conscious ratsNaltrexone Facilitates Learning and Delays Extinction by Increasing AMPA Receptor Phosphorylation and Membrane Insertion.Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor systemSubgroups among mu-opioid receptor agonists distinguished by ATP-sensitive K+ channel-acting drugs.Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexoneAntinociceptive effects of the novel opioid peptide BW443C compared with classical opiates; peripheral versus central actions.The physiological relevance of low agonist affinity binding at opioid mu-receptors.Evaluation of opioid-induced antinociceptive effects in anaesthetized and conscious animals.ICI 204448: a kappa-opioid agonist with limited access to the CNS.Effects of competitive and noncompetitive antagonists of the N-methyl-D-aspartate receptor on the analgesic action of delta 1- and delta 2-opioid receptor agonists in mice.Pre-incubation of guinea-pig myenteric plexus with beta-funaltrexamine: discrepancy between binding assays and bioassaysBremazocine is an agonist at kappa-opioid receptors and an antagonist at mu-opioid receptors in the guinea-pig myenteric plexus.Effects of mu-opioid receptor agonists on circulatory responses to simulated haemorrhage in conscious rabbitsThe use of [3H]-[D-Pen2,D-Pen5]enkephalin as a highly selective ligand for the delta-binding site.Selectivities of opioid peptide analogues as agonists and antagonists at the delta-receptor6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists.Spectrum of the mu, delta- and kappa-binding sites in homogenates of rat brain.Characterization of the opiate receptor population mediating inhibition of VIP-induced secretion from the small intestine of the ratMethadone block of K+ current in squid giant fiber lobe neuronsMolecular recognition of opioid receptor ligands.Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in ratsAllosteric modulation model of the mu opioid receptor by herkinorin, a potent not alkaloidal agonist.The relationship between the pharmacokinetics and pharmacodynamics of spinal opioids. Minireview based on a doctoral thesis.Unexpected prosecretory action component of loperamide at mu-opioid receptors in the guinea-pig colonic mucosa in vitroBinding and structure-activity-relation of benzo[f]isoquinoline- and norcodeinone-derivatives at mu-opioid receptors in the rat cerebral cortex.Characterization of opioid receptors in the cat carotid body involved in chemosensory depression in vivo.The contributions of mu-, delta- and kappa-opioid receptors to the actions of endogenous opioids on spinal reflexes in the rabbit.Alkylation with beta-funaltrexamine suggests differences between mu-opioid receptor systems in guinea-pig brain and myenteric-plexus.Inability of an opioid antagonist lacking negative intrinsic activity to induce opioid receptor up-regulation in vivo.Spinal antinociceptive actions of mu- and kappa-opioids: the importance of stimulus intensity in determining 'selectivity' between reflexes to different modalities of noxious stimulusLocal opioid-sensitive afferent sensory neurones in the modulation of gastric damage induced by Paf.Morphine-induced in vivo release of spinal cholecystokinin is mediated by delta-opioid receptors--effect of peripheral axotomy.
P2860
Q24614482-429A7ECC-2ECC-4DD6-8D06-B90494558080Q24681935-D5FA5FD9-11F4-49A7-8BD8-02808B41B595Q28259198-F26CD4E6-CF78-4B3B-AAF8-648EE2A78CF6Q28287612-379249A6-C62B-4C37-81C3-8CD91DF5C2BBQ28343904-6ABE4FE6-3C80-4F76-9EFE-A859C436B0C2Q28379396-CB37EC3B-D086-4E67-BE7A-44AA9FF6507AQ30405854-52A44CF2-D8A7-4C76-B691-14FA5950AB87Q30671455-A992B369-259E-435D-9426-AB756670BA14Q34410429-A00EE245-5D12-4654-A2F2-8DD91E552E67Q34561447-DE87E12B-4318-4873-9AC5-FAFA13AEA152Q34793265-B5EF851E-27E5-4499-82A9-14B08494F20FQ35110295-99FC9F4C-A083-4651-818C-5834C408B8DFQ35755177-DD3C434A-CFE6-471E-8A86-71C56392EFCBQ35755586-A7B3FA5C-F883-4EB6-97C3-60AD31EB53D3Q35755809-528DB4D7-5717-478E-A540-33A887684348Q35756335-871EC39E-005D-4747-94FA-8B038A74419DQ35884593-6080A9BE-4780-4612-8D9C-CA4144CEC8A9Q35886347-363370F1-8438-4F9C-9B3A-909E7B59E935Q35887293-09CB9883-8D7D-4C96-8D36-58462EEA1C48Q35888477-826C8ABC-3585-4854-AA06-550A2122747CQ36003985-60EE5724-407D-4046-916F-2C2AF2534CAAQ36004219-38D17AFF-BF67-48D5-ADB9-37B4877C1090Q36090988-F2F13093-F47A-4960-A407-6DF03D87F971Q36097433-F92431B1-40C8-40D6-BC65-F67E2DDF5F30Q36098039-77FD0909-0C38-461D-B02B-8C551A6BA526Q36415739-0486D9AB-0B72-4411-84D7-D64CCE0C1365Q36439154-86684B0D-2DD2-4A87-BD8E-84B762364865Q36480105-143B7965-DAD8-4EE7-9E2C-1576187BB1E9Q36932895-4DAF6CA3-3068-405B-9A1E-6C26338EE6B9Q38736870-E1FA6CD6-68CC-4104-8A5A-8A41CE48E103Q39471542-35F97092-B5B2-4682-B38A-32FEF3B70A31Q41872646-C5031B6A-BA48-4F48-BAEC-A637465689B4Q41950700-21CEF1A2-FC74-444D-AD79-A14C6BDE3D04Q42028750-D8DB8D44-F6A4-4AEF-BC37-012DEC08BE46Q42119799-524FBEA9-413B-4569-9118-47C3CE6327B7Q42178306-73A876FB-BB88-4806-AA90-4F36FA907EAAQ42560664-FD657B7C-AD5F-4020-B2EC-BDC5FEBB9E48Q42847477-E211B7E4-A6F0-4AF7-B283-C1B877E64F4EQ42847868-5742F174-E9F4-44D1-A13F-D133815510BFQ43658586-5B5442DB-55E2-4371-A234-3C2A6918388E
P2860
The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年学术文章
@wuu
1982年学术文章
@zh-cn
1982年学术文章
@zh-hans
1982年学术文章
@zh-my
1982年学术文章
@zh-sg
1982年學術文章
@yue
1982年學術文章
@zh
1982年學術文章
@zh-hant
name
The binding spectrum of narcot ...... ist and antagonist properties.
@en
The binding spectrum of narcot ...... ist and antagonist properties.
@nl
type
label
The binding spectrum of narcot ...... ist and antagonist properties.
@en
The binding spectrum of narcot ...... ist and antagonist properties.
@nl
prefLabel
The binding spectrum of narcot ...... ist and antagonist properties.
@en
The binding spectrum of narcot ...... ist and antagonist properties.
@nl
P2093
P2860
P356
P1476
The binding spectrum of narcot ...... ist and antagonist properties.
@en
P2093
H W Kosterlitz
S J Paterson
P2860
P2888
P304
P356
10.1007/BF00495865
P577
1982-06-01T00:00:00Z